 Cardiotonic Agents
"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 2 | 2 | | 2014 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, Hylander Møller M, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021 11 01; 49(11):e1063-e1143.
-
Barefield DY, McNamara JW, Lynch TL, Kuster DWD, Govindan S, Haar L, Wang Y, Taylor EN, Lorenz JN, Nieman ML, Zhu G, Luther PK, Varró A, Dobrev D, Ai X, Janssen PML, Kass DA, Jones WK, Gilbert RJ, Sadayappan S. Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury. J Mol Cell Cardiol. 2019 04; 129:236-246.
-
Abidov A, Dilsizian V, Doukky R, Duvall WL, Dyke C, Elliott MD, Hage FG, Henzlova MJ, Johnson NP, Schwartz RG, Thomas GS, Einstein AJ. Aminophylline shortage and current recommendations for reversal of vasodilator stress: An ASNC information statement endorsed by SCMR. J Nucl Cardiol. 2019 Jun; 26(3):1007-1014.
-
Suleiman MS, Underwood M, Imura H, Caputo M. Cardioprotection during Adult and Pediatric Open Heart Surgery. Biomed Res Int. 2015; 2015:712721.
-
Dedkova EN. Some Like it Hot: Cardioprotective Effect of Curcumin in Chronic Kidney Disease : Editorial to: "Cardioprotection by Curcumin Post-Treatment in Rats with Established Chronic Kidney Disease" by S. Hernandez-Resendiz et al. Cardiovasc Drugs Ther. 2015 Apr; 29(2):101-3.
-
Jones RL, Sandri MT. Cardio-oncology: a special focus issue from Future Oncology. Future Oncol. 2015; 11(14):1993-4.
-
Rangel MO, Morales Demori R, Voll ST, Wassouf M, Dick R, Doukky R. Severe chronic kidney disease as a predictor of benefit from aminophylline administration in patients undergoing regadenoson stress myocardial perfusion imaging: A substudy of the ASSUAGE and ASSUAGE-CKD trials. J Nucl Cardiol. 2015 Oct; 22(5):1008-18.
-
Ballany W, Mansour K, Morales Demori R, Al-Amoodi M, Doukky R. The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial. J Nucl Cardiol. 2014 Jun; 21(3):496-502.
-
Ueta CB, Oskouei BN, Olivares EL, Pinto JR, Correa MM, Simovic G, Simonides WS, Hare JM, Bianco AC. Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice. Mol Endocrinol. 2012 May; 26(5):809-18.
-
Doukky R, Morales Demori R, Jain S, Kiriakos R, Mwansa V, Calvin JE. Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". J Nucl Cardiol. 2012 Jun; 19(3):448-57.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|